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ABSTRACT
Purpose To overcome the limitation of insufficient hardness
during the production of rapidly disintegrating orally dispersible
tablets (ODTs). Furthermore, we investigated the properties
and usefulness of functionalized calcium carbonate (FCC) as a
new pharmaceutical excipient for the production of ODTs.
Methods A highly sensitive tensiometer-based method was
developed to measure kinetics of weight loss during tablet
disintegration. With this method we were able to determine
the residence time of tablets placed on a basket immersed into
a test medium. The shapes of tensiometer plots allowed us to
categorize substances into four different types of disintegration.
Results At the same volume and hardness, the tablet formula-
tions with FCC showed a significantly higher porosity (over
60%) than all other formulations. Residence time depended
mainly on the tablet composition rather than on porosity. When
combined with disintegrants, FCC formulations exhibited favor-
able disintegration properties, comparable to those of the
marketed drug risperidone oro (disintegration time ca. 10 s).
Conclusions Oral dosage forms - based on the new pharma-
ceutical excipient FCC - can be designed to have a short disinte-
gration time combined with good mechanical strength. Due to
these properties, FCC can be used for the preparation of ODTs.
KEY WORDS disintegration . ODT . porosity . residence
time . tensiometer
INTRODUCTION
Orally dispersible/disintegrating tablets (ODTs) constitute a
solid, single-unit dosage form which instantaneously
disperses/dissolves in the saliva (1). ODTs can be prepared
by different techniques, such as freeze drying (2,3), mould-
ing (4), spray drying (5), and mass extrusion (6). Depending
on the technique, the final form dissolves very rapidly (5–
15 s), but may be associated with low mechanical strength,
high production costs, low drug content, or limited stability
(7). The easiest technique to prepare ODTs is by direct
compression. With conventional equipment, a limited num-
ber of process steps, and commonly available excipients,
ODTs containing large amount of active ingredients can
be produced at low costs. However, disintegration capacity
of ODTs produced by this technique is limited by the size
and hardness of the tablets (8,9). Increased compression
force applied during tableting leads to harder tablets thus
increasing disintegration time (10). Consequently, ODTs
with optimal disintegration properties are often small
and/or have a low hardness and higher friability (8).
In accordance with the European Pharmacopeia, ODTs
should disintegrate within 3 min when tested with the con-
ventional disintegration apparatus (11). The American Food
and Drug Administration (FDA) requires an in-vitro disinte-
gration time of approximately 30 s or less (12,13). The
disadvantage of the conventional disintegration apparatus
is poor discrimination among rapidly disintegrating tablets
(14). Furthermore, the volume of the test medium (900 ml) is
relatively large, compared with the volume of saliva in the
mouth cavity (less than 6 ml) (15). Several techniques have
been proposed to measure the disintegration time of ODTs
(14,16–23). For example, one research group used the force
measurement detection to analyze the forces developed
during the disintegration process due to water absorption
(24). In our current work, we adapted the standard liquid
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absorption measurement by means of a tensiometer (25) to
accurately determine tablet disintegration time and mimic
disintegration in the patient’s mouth cavity. This method
employs the microbalance of the tensiometer to detect ki-
netics of weight loss during tablet disintegration. In addition,
the proposed method provides quantitative information on
dispersion kinetics, i.e., speed; ability to readily disperse in
small volumes of liquid (e.g., teaspoon); and to detect for-
mation of big swollen lumps.
Disintegration time of an ODT depends on the porosity
of the tablet. The rate of water uptake increases with higher
porosity of the ODT. Thus, disintegration rate increases
because of faster wetting of the tablet (26). On the other
hand, higher porosity of the ODT affects the hardness of the
resulting tablets hence compromising further processing of
formulations. Consequently, an ideal ODT combines two
controversial properties, i.e., higher porosity and higher
hardness. An excipient with combined functionality (highly
porous and providing strong grip between particles) has
been identified in paper industry.
Ridgway et al. modified a natural ground calcium car-
bonate to enhance porosity up to 60% (v/v) and enlarge the
surface area. This functionalized calcium carbonate (FCC)
absorbs water at a faster rate and is able to absorb 10 times
more fluid than conventional calcium carbonate (27).
The manufacturing process of FCC shows some similar-
ities to the production of precipitated calcium carbonate, an
established pharmaceutical excipient. Both substances are
produced by decomposition, once in aqueous solution (pre-
cipitated calcium carbonate) and once under acidic condi-
tions (FCC). The different conditions and different
concentrations lead to different shapes and different particle
size distributions of the particles (28,29).
The aim of the current work was to investigate the
properties and usefulness of FCC as a new pharmaceutical
excipient in the production of ODTs. Performance of FCC
was compared to that of other commonly used excipients
such as microcrystalline cellulose (MCC 102 and MCC
burst), and FlowLac (fillers) and AcDiSol, VivaStar, and
Kollidon CL as disintegrants.
MATERIALS AND METHODS
Materials
FCC (VP-220976 S02, Omya, Switzerland), directly com-
pressible calcium carbonate (Barcroft™ CS90, SPI Pharma,
Germany), calcium carbonate (PharMagnesia CC Type
Natur 120, Lehmann & Voss & Co., Germany), microcrystal-
line cellulose (MCC SANAQ® 102, Pharmatrans Sanaq AG,
Switzerland), and lactose monohydrate (FlowLac® 100,
Meggle, Germany) were used as fillers. As disintegrating
agents, modified cellulose gum (Ac-Di-Sol®, FMC, USA),
insoluble, cross-linked polyvinylpyrrolidone (Kollidon® CL,
BASF, Germany) and sodium starch glycolate (Vivastar®,
JRS, Germany) were selected. A special kind of microcrystal-
line cellulose (MCC SANAQ® burst, Pharmatrans Sanaq
AG, Switzerland) was used both as filler and disintegrant.
The market ODT formulation, Risperidone-Mepha® 0.5
oro tablets, was used as a reference of a market.
Isopropyl myristate (Hänseler AG, Switzerland) was chosen
as a dispersant for particle size distribution measurements.
Methods
Characterization of FCC
The true density of FCC was determined by helium
pycnometry (Micromeritics AccuPyc 1,330, USA).
Scanning electron microscopy (SEM) images were
obtained using the FEI/Philips XL30 FEG apparatus
(Philips, Netherlands). Before measurements, the samples
were sputtered with a 40 nm gold layer by a sputter coating
machine (MED 020, BalTec, Liechtenstein).
Pore size distribution of FCC was determined with a
mercury porosimeter (AutoPore IV 9,500, Micromeritics
Instrument, USA). Low-pressure mercury intrusion ranged
from 3.59 kPa to 206.64 kPa. During high-pressure mercury
intrusion, the pressure ranged from 206.64 kPa to
206.78 MPa. For both high- and low-pressure intrusion,
equilibration time was 10 s.
To measure the specific surface area, Nova 2000e
(Quantachrome Instruments, USA) was used with the five-
point BET (Brunauer, Emmett, Teller) method. After
degassing the samples for 12 h at room temperature, the
samples were measured with nitrogen at constant temperature
(77.4 K). The measurement was performed in duplicate.
Particle size distribution was determined with the
Mastersizer X long bed (Malvern Instruments, UK). For
MCC 102, MCC burst, FlowLac, Barcroft, AcDiSol and
VivaStar, the dry powder feeder (Malvern) was used. These
measurements were performed in triplicate. Kollidon and
FCC were dispersed in isopropyl myristate and then ana-
lyzed (in duplicate) by using the small volume sample pre-
sentation unit (Malvern). The medians of the particle
diameter and their standard deviations are shown.
Tablet Preparation
All powders and formulations were mixed by using a tumbling
mixer (Turbula T2C, Switzerland) for 10 min at 32 rpm. The
tablets were compressed by a single punch press (Korsch EK0,
Berlin) with 11 mm round flat tooling. The punch gap was
adjusted to compact 500 mg of FCC powder into a tablet with
a hardness of 100 N. The resulting tablet had a height of
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5.30 mm. This setting for the punch gap was kept constant for
all other mixtures. The target hardness of 100 N was obtained
by changing the mass of the compacts. The powder was
introduced manually into the die. After compacting, the tab-
lets were stored in closed glass bottles in the room at 24±2°C
and at 40±5% relative humidity (measured values) for 30 days
to allow enough time for expansion.
We did not use any lubricant in order to avoid potential
influence of the lubricant distribution on the properties of
FCC in combination with a disintegrant. Due to manual
tableting, the speed of compaction was slower than with an
automated process, i.e. using hopper. The lower compres-
sion speed caused less friction; hence the tablets were not
damaged during ejection.
We could obtain the same tablet hardness with 0.5%
magnesium stearate. In order to exclude potential influence
of lubricants, we compressed 300 mg S02 powder at 4 kN.
For the tablets without magnesium stearate, we obtained a
hardness of 124±8 N, whereas the tablets with magnesium
stearate showed a hardness of 126±5 N.
The concentration of the disintegrant was kept constant
and comprises of 3% w/w in accordance to general recom-
mendations (30). Our focus was set on the comparison of
different filler excipients (e.g. FCC) on the disintegration
behavior in presence of different disintegrants. In addition,
our earlier experience in application of the percolation
theory to the tablet disintegration and water uptake has
revealed that the percolation threshold is located at 3%v/v
for AcDiSol (31). This value could be corroborated by
computer-based simulations of the percolation thresholds
carried out by Garboczi et al. (32). In accordance with these
results the optimal theoretical value lays in the area of 3%
v/v for elongated particles with aspect ratio approx. 20.
Tablet Characterization
To determine the mean tablet weight, tablets (n=13) were
weighted on an electronic balance (Mettler Toledo, type
XS204 DeltaRange, Switzerland). Tablet diameter (n=13)
was measured with a micrometer screw (Mitutoyo Model
CD-15CPX, Japan), and tablet thickness (n=13) was deter-
mined with a dial indicator (Compac type 532G,
Switzerland). Friability was measured by an ERWEKA
(type TA200, Germany). The hardness of the tablets (n=3)
was checked with a hardness tester (Tablet tester 8 M,
Switzerland). To determine the true densities, a helium
pycnometer was used (Micromeritics AccuPyc 1,330,
USA). Porosity ε (%) of the tablets was calculated with the
Eq. 1, as follows:
" ¼ 1
m
ρ
p  r2  h
 
 100 ð1Þ
where m is the tablet weight (g), ρ the true density of the
powder mixture (g/cm3), r the radius of the tablet (cm), and
h the height of the tablet (cm).
Method for Characterization of Disintegration and Dispersion
Kinetics
To characterize disintegration and dispersion kinetics of the
tablets (n=3, for FCCwithout disintegrants n=2) a tensiometer
(Krüss Processor Tensiometer K100MK2, Germany) was
used. The experimental setup was composed of a special
metal-wire basket (Fig. 1a) which was attached to the micro-
balance of the tensiometer with four nickel wires. For the
measurement of small tablets (such as risperidone oro tablets),
the mesh size was reduced by a nickel wire to a size of 4 mm×
4.5 mm. As shown in Fig. 1b, the basket was immersed to a
defined depth (12 mm) into a beaker. The beaker was filled up
to the edge with distilled water. The beaker was heated (37°C
±1°C) by the surrounding thermostatic water bath.
Weight loss versus time was recorded by the tensiometer
software. Figure 1c shows a schematic representation of this
plot. The tablet was placed manually on the basket immersed
in the water. With the aid of the tensiometer software, the
mass was plotted against the time. The time point at which the
tablet reached the basket and disintegration induced by water
absorption started was indicated as t0. At this stage, the weight
was increased due to water uptake. This was reflected as
weight increase on the profiles. The weight decrease was
explained as tablet disintegration upon water uptake. The
end of tablet disintegration was indicated by the leveling off
of the profile. This event was referenced as t1. The difference
between t1 and t0 (t1-t0) was the tablet residence time on the
basket. Residence time is a measure of disintegration time and
is a good indicator of the time needed to disperse the tablet in
the mouth cavity or on a spoon. To determine t0 and t1, the
two linear equations were fitted with OriginPro version 8.5
(OriginLab Corporation, USA). A user-defined double linear
curve fit was programmed with Eq. 2.
mabsorption ¼ m0 þ k0  t t < tc
melimination ¼ m0 þ k0  tc þ k1 t tcð Þt  tc ð2Þ
where m is the weight (g) and t is the time (s).
If ma and me are set equal to 0 and Eq. 2 is solved for t, the
following equations are obtained:
t0 ¼ m0k0
t1 ¼ tc  m0þk0tck1
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To calculate the residence time, Eq. 3 was used.
Δt ¼ t1  t0 ¼ tc  m0þk0tck1 
m0
k0
ð3Þ
In addition to the residence time, the disintegration de-
gree was calculated with Eq. 4:
n ¼ 1 mfinal
mmax
 
 100 ð4Þ
where n is the disintegration degree (%) and m is the weight
(g). For mmax the weight at time point tc was used, and mfinal
is the weight at leveling off of the profile (Fig. 1c).
Kinetics of Water Absorption (Tensiometer)
Water absorption capacity of the tablets (n=3) for each lot was
measured with a tensiometer (Krüss Processor Tensiometer
K100MK2, Germany) in a water bath (37°C±1°C). The
tablet was placed in a glass tablet holder with a ceramic filter
bottom. With the help of the software, time was plotted
against mass gain. The slope of this function indicated the
speed of water absorption, and the saturation level
corresponded to the relative amount of absorbed water. To
calculate the slope, the values for the time points between 6
and 9 s were taken into account. OriginPro version 8.5
Fig. 1 (a) Schematic representation of the basket. (b) Schematic representation of the experimental setup for measuring the residence time. (c) Schematic
representation of the mass versus time plot from the tensiometer software.
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(OriginLab Corporation, USA) was used for curve fitting and
the evaluation of tensiometer plots.
RESULTS
Properties of Fillers (F) and Disintegrants (D)
Figure 2a-c shows SEM pictures of FCC at different mag-
nifications. The size of the FCC particles was around 7 μm.
The particles showed a multitude of thin lamellae that
formed a porous meshwork. Figure 2d illustrates the mer-
cury porosimetry plot of FCC.
Table I shows the true densities and medians of the
particle diameter of the used substances. With the BET
method a specific surface area of 62.14±0.19 m2/g was
measured for the FCC particles.
Evaluation of Tablet Properties
Table II lists the properties of the tablets. At the same volume
and hardness (100 N), the tablets with FCC and MCC 102
were the lightest (around 500 mg). By comparison, CS90
tablets were approx. 1.7 times heavier (approx. 840 mg) than
the tablets consisting of FCC and MCC 102. Friability was
1.0% to 1.7% for all tablets except the formulations with
MCC 102, where a friability of approx. 0.5% was reached.
Although volume and hardness of the tablets were kept con-
stant, porosity of the tablets varied strongly between the
different tablet formulations. Tablet formulations with FCC
had a porosity of over 60% whereas the MCC 102-based
tablets exhibited a porosity of only 40% at the same weight.
With porosities of about 25% and 35%, the tablets consisting
of FlowLac and MCC burst were less porous than MCC 102
tablets. Formulations with CS90 had a porosity of approx.
35% and weighed approx. 840 mg.
Calcium carbonate Natur 120 was not suitable for the
preparation of tablets with the desired properties. The target
hardness (100 N) was not reached due to capping of the tablets.
Table III shows the residence times and disintegration
degrees obtained after a double linear curve fit of tensiom-
eter weight versus time plots (Fig. 1).
In addition, Table III indicates the speed of water absorp-
tion and amount of absorbed water after 90 s. Some formu-
lations with FCC, MCC 102, and MCC burst reached a
water absorption speed of more than 50 mg/s. Only MCC
102 and MCC burst formulations absorbed water at a speed
of more than 100 mg/s. The formulations with MCC burst
showed the highest absolute amount of absorbed water.
As pointed out above, an ODT should disintegrate with-
in 3 min if tested with the standard disintegration test
according to the European Pharmacopeia (11). Figure 3
illustrates the influence of tablet composition on residence
time. The horizontal line indicates a residence time of
3 min. With the fillers FCC and FlowLac, three formula-
tions in each case had a residence time of less than 3 min. In
comparison with FlowLac, the FCC formulations had a sig-
nificantly shorter residence time. FCC formulations showed
Fig. 2 (a-c) SEM pictures
of FCC (magnifications: (a) x 300,
(b) x 3,000, and (c) x 10,000).
(d) Mercury porosimetry
plot of FCC.
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fast disintegration comparable to that of MCC burst and
MCC 102 formulations. It is important to note that FCC
formulations compared well with the reference tablets, risper-
idone oro. On the other hand, it has to be kept in mind that
FCC had to be used in combination with a disintegrant to
trigger the fast dispersion. For all tablets with a residence time
below 3 min, a disintegration degree between 85% and 100%
was calculated. Nevertheless, Table III shows that not all of
the tablet formulations had residence times below 3 min. We
marked the residence time values as ∞ if calculated residence
time (Δt) indicated that water absorption was not followed by
tablet disintegration.
DISCUSSION
Tensiometer Method
The present work describes a novel strategy for the design of
orally dispersible tablets (ODT). Functionalized calcium car-
bonate (FCC) was used as the main pharmaceutical excipient
for ODTs, which are characterized by a very short disintegra-
tion time (i.e. <10 s). This rapid process is a challenge, in that
conventional disintegration protocols according to the
European Pharmacopeia cannot be used. This standard meth-
od relies on a vertically moving sample holder. This leads to
forced disintegration of tablets due to mechanical stress. For
example, formulations containing spray dried calcium carbon-
ate (i.e. the Barcroft formulations), did not disintegrate in an
unstirred solution. Upon agitation only, tablet fragments are
dislocated from the tablet surface. FlowLac based formulations
Table I True Density and Median Particle Diameter of the Substances
(Where F Stands for Function as Filler and D Stands for Disintegrant)
Substance Function in a
formulation
True density
(g/cm3)
Median particle
diameter (μm)±SD
FCC F 2.7382 7.28±0.05
Barcroft CS90 F 2.5233 163.52±10.00
MCC 102 F 1.5583 120.65±1.31
FlowLac F 1.5412 150.37±2.19
MCC burst F+D 1.5337 64.04±0.14
AcDiSol D 1.5996 43.74±0.06
VivaStar D 1.4778 41.20±0.12
Kollidon CL D 1.2374 91.64±0.81
Table II Tablet Properties
Tablet formulation Diameter
(mm) (n=13)
Thickness
(mm) (n=13)
Weight (mg) ± SD
(n=13)
Hardness
(N) ± SD (n=3)
Friability (%)
(n=1)
Porosity (%)
FCC 11.02±0.01 5.30±0.02 499.4±2.9 117.3±15.0 1.06 64
FCC+3% AcDiSol® 11.03±0.01 5.41±0.01 498.9±1.9 99.7±9.6 1.32 64
FCC+3% Viva Star® 11.01±0.01 5.36±0.05 502.3±0.8 107.0±3.5 1.67 64
FCC+3% Kollidon® CL 11.02±0.01 5.14±0.01 499.2±1.0 116.7±19.2 1.18 62
FCC+3% MCC burst 11.03±0.01 5.20±0.09 500.8±1.6 111.7±21.1 1.10 63
Barcroft™ CS90 11.07±0.00 5.47±0.01 851.7±1.4 95.3±1.2 1.12 36
Barcroft™ CS90+3% AcDiSol® 11.08±0.00 5.58±0.01 845.3±1.2 88.3±2.5 1.25 37
Barcroft™ CS90+3% Viva Star® 11.08±0.01 5.50±0.01 845.9±1.3 94.7±2.9 1.14 36
Barcroft™ CS90+3% Kollidon® CL 11.07±0.00 5.51±0.01 833.0±1.5 98.3±3.8 1.12 37
Barcroft™ CS90+3% MCC burst 11.06±0.00 5.49±0.01 836.9±1.1 95.7±0.6 1.20 36
FlowLac® 11.05±0.01 5.32±0.01 594.4±2.7 88.3±3.2 1.46 24
FlowLac®+3% AcDiSol® 11.06±0.01 5.33±0.01 593.3±1.3 86.3±2.1 1.28 25
FlowLac®+3% Viva Star® 11.06±0.00 5.34±0.01 598.7±0.8 88.3±5.0 1.40 24
FlowLac®+3% Kollidon® CL 11.06±0.00 5.35±0.02 595.0±1.2 89.3±3.2 1.50 24
FlowLac®+3% MCC burst 11.06±0.01 5.34±0.01 605.4±2.7 97.3±7.8 1.16 23
MCC 102 11.06±0.01 5.53±0.02 489.0±3.6 93.0±7.5 0.54 41
MCC 102+3% AcDiSol® 11.06±0.01 5.55±0.02 494.0±2.8 93.3±2.1 0.38 41
MCC 102+3% Viva Star® 11.07±0.01 5.54±0.03 498.3±2.3 96.0±1.0 0.51 40
MCC 102+3% Kollidon® CL 11.06±0.01 5.55±0.02 487.9±1.8 98.3±3.5 0.48 41
MCC 102+3% MCC burst 11.07±0.01 5.54±0.02 493.6±2.0 92.3±3.5 0.59 41
MCC burst 11.10±0.01 5.83±0.03 566.6±2.9 88.7±3.8 1.52 34
MCC burst+3% AcDiSol® 11.09±0.01 5.75±0.03 563.3±1.9 94.0±3.5 1.38 34
MCC burst+3% Viva Star® 11.08±0.01 5.84±0.02 573.8±1.8 90.0±0.0 1.64 33
MCC burst+3% Kollidon® CL 11.10±0.01 5.82±0.02 566.5±1.3 86.7±3.8 1.53 34
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have a similar behavior in that tablets are fractured by agita-
tion. However, this “accelerated” or “forced” disintegration
does not reflect the intended use of our ODT formulations.
Here, disintegration in unstirred liquid (i.e. in a spoon prior to
oral administration) is needed. We were therefore forced to
develop our own disintegration method. As expected, the dis-
integration time for most formulations was shorter for the
standard method as compared to our tensiometer method. In
particular, MCC based formulations swell only and do not
disintegrate if not agitated. An additional advantage of our
tensiometer based method is its ability to monitor rapid disin-
tegration processes with very high precision. In addition, a
slight modification of the experimental setup allows for quan-
tification of the absorbed amount of water. Thereby, the type,
volume, and temperature of fluid can be varied.
FCC as a New Pharmaceutical Excipient
for the Production of ODTs
Comparison between FCC and Barcroft showed considerable
differences in the porosity. FCC-containing formulations (with
disintegrants) showed the best results. Formulations combining
FCC with a disintegrant disintegrated/dispersed within a few
seconds. Thereby, the mode of action of the different
disintegrants had no significant influence on the residence
time. Furthermore, all formulations of FCC combined with
disintegrants belonged to the disintegration type I and showed
a disintegration degree of 100%. We successfully produced
tablets with marked porosity and high hardness.
Properties of FCC
Several studies have demonstrated that porosity has a sur-
prisingly low impact on the disintegration behavior of FCC.
Figure 4 correlates speed of water absorption and the
absorbed amount of water after 90 s for FCC combined
with different excipients. Speed of water absorption and
absorbed amount of water after 90 s for each formulation
were influenced by the disintegrants only.
For FCC as well as all other excipients, no correlation
could be shown between the tablet weight and disintegration
degree (Table II and III). Disintegration degree was only
dependent on the composition of the tablet formulations.
Residence time also depended on the tablet composition and
Table III Calculated Parameters for Residence Time, Disintegration Degree, and Kinetic of Water Absorption
Tablet formulation Residence
time (s)
Disintegration
degree (%)
Disintegration
type (I-IV)
Amount of absorbed
water after 90 s (g)
Speed of water
absorption (mg/s)
FCC ∞ 0 II 0.189±0.011 4.5±0.33
FCC+3% AcDiSol® 8.92 100 I 1.232±0.018 80.4±2.69
FCC+3% Viva Star® 11.94 100 I 1.599±0.055 86.8±3.95
FCC+3% Kollidon® CL 9.53 100 I 0.816±0.007 37.9±0.92
FCC+3% MCC burst 4858.26 2 II 0.229±0.008 4.9±0.54
Barcroft™ CS90 ∞ 0 II 0.115±0.013 0.7±0.09
Barcroft™ CS90+3% AcDiSol® 7703.4 4.7 II 0.080±0.033 1.9±0.05
Barcroft™ CS90+3% Viva Star® 197.68 100 III 0.263±0.015 5.9±0.29
Barcroft™ CS90+3% Kollidon® CL ∞ 0 II 0.074±0.037 1.6±0.24
Barcroft™ CS90+3% MCC burst ∞ 0 II 0.113±0.021 1.1±0.19
FlowLac® 61.92 100 III 0.311±0.044 5.4±2.06
FlowLac®+3% AcDiSol® 127.85 100 III 0.322±0.016 5.5±0.29
FlowLac®+3% Viva Star® 194.2 100 III 0.667±0.026 16.2±1.64
FlowLac®+3% Kollidon® CL 65.09 100 III 0.375±0.017 9.8±0.33
FlowLac®+3% MCC burst 64.57 85 III 0.344±0.045 9.1±0.95
MCC 102 ∞ 0 II 0.807±0.040 79.2±17.95
MCC 102+3% AcDiSol® 1681.78 47.2 IV 1.306±0.017 82.3±13.61
MCC 102+3% Viva Star® 9.65 99.1 I 1.840±0.050 152.9±27.09
MCC 102+3% Kollidon® CL ∞ 0 IV 0.877±0.016 70.1±15.83
MCC 102+3% MCC burst ∞ 0 II 0.847±0.044 71.0±12.97
MCC burst ∞ 0 IV 1.741±0.059 96.6±5.63
MCC burst+3% AcDiSol® 5.92 96.3 I 1.864±0.052 70.9±3.22
MCC burst+3% Viva Star® 10.4 100 I 2.347±0.034 98.1±4.64
MCC burst+3% Kollidon® CL ∞ 0 IV 1.826±0.054 104.9±13.24
Risperidone oro 17.26 100 I - -
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was not affected by the porosity or weight of the tablets. This
latter finding was surprising since it has been suggested re-
cently that porosity might be an important property of ODTs
(26). Again, the combination of filler and disintegrants seems
to be the decisive factor, which appears to be a unique
property of FCC. All other excipients studied did not show
such a linear correlation (data not shown). This result suggests
that the speed of water absorption is modulated by
disintegrants. In the case of FCC, water absorption is a pre-
requisite for disintegration since pure FCC neither absorbs
water nor disintegrates. Thus, the choice of a specific
disintegrant is not a critical factor.
From the percolation theory point of view, disintegration
occurs above critical concentrations (threshold) of the
disintegrant (33). In our study, all formulations had
disintegrant concentrations close to the theoretically predicted
critical value, i.e., approx. 3% (v/v). At these concentrations,
the rate of disintegration is mostly governed by the type of
disintegrant rather than by tablet porosity (33).
Definition of Disintegration Patterns
We were able to distinguish four typical disintegration pat-
terns (Table III and Fig. 5).
First, excipients such as FCC and the commercial refer-
ence, ODT formulation of risperidone oro, showed a classical
disintegration pattern. Initially, absorption of water is faster
than disintegration (increase in mass). After reaching a peak,
the tablet continuously dispersed (decrease in mass) into very
small particles. This desirable property has been termed dis-
integration type I. In sharp contrast, non-modified calcium
carbonate particles (Barcroft) did not disintegrate. This profile
was characterized by fast initial water absorption only. After
saturating the pores with water, the speed of the water ab-
sorption declined continuously. Some formulations reached a
plateau, whereas other formulations were still able to absorb
more water, forming a large swollen lump. This profile was
defined as disintegration type II. FlowLac was a typical rep-
resentative of disintegration type III, which was characterized
by nonuniformity in the disintegration phase caused by larger
fragments falling off the tablet and then through the mesh.
These parts needed some more time on the bottom of the
beaker to disperse completely. We could not establish whether
the fragments that had come loose were still dry on the inside.
Finally, cellulose-based excipients (i.e., MCC 102 and MCC
burst) combined properties of type I and type II disintegration
patterns: initial phase of swelling followed by partial disinte-
gration. This profile termed disintegration type IV.
Owing to the new and very sensitive tensiometer method,
ODTs could be categorized based on their disintegration
profiles (Table III).
Fig. 3 Influence of tablet
composition on
residence time.
Fig. 4 Correlation plot between speed of water absorption and absorbed
amount of water after 90 s.
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Quantitative Model for Residence Time
Disintegration profiles can be evaluated using a user-defined
double linear curve fit model. In the majority of cases, the
values of residence time determined from the tensiometer plot
(Fig. 5) agreed well with the calculated values in Table III.
Quantitative evaluation for profiles of type III was difficult
due to the larger parts of the tablets that had fallen through
the basketmesh (i.e., without dispersing/disintegrating), hence
shortening the residence time. Another limitation of themodel
was the discrepancy between measured and calculated values
for residence time for a few formulations that showed an
exponential function within the tensiometer plot.
It should be emphasized, that disintegration of tablets is a
complex process. Figure 1c shows a disintegration profile,
which is characterized by a series of sequential events. In a
first step, the tablet was wetted by the medium, followed by
medium absorbance and disintegration. Thus, the tablet
mass increased until equilibrium was reached between liq-
uid sorption and mass decrease due to disintegration.
Afterwards, the disintegration predominated the water sorp-
tion resulting in a net loss of mass.
In many instances (Fig. 5), the disintegration pattern is
more complex. For example, some materials first soak up
liquid very fast and subsequently start to disintegrate by
heterogeneous fractionation. Other materials like FCC soak
up water at moderate speeds, leading to continuous disinte-
gration and loss of mass.
Several mathematical models can be used to describe
these processes. For example, the concurrent effects could
be modeled by the system of two differential equations (here
combined into one equation):
d
dt
mðtÞ ¼ M0ekat  kemðtÞ;
Fig. 5 Tensiometer plots for 4 types of disintegration kinetics (mass versus time). Re-normalized curve (with mass maximum at 0.0223 g).
Fig. 6 Correlation plot between the amount of absorbed water after 90 s
and residence time for the different disintegration types.
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where m(t) is mass detected by tensiometer, t is the time, M0
is compact mass in the test media, and Ka and Ke are the
absorption and disintegration speed constants, respectively.
However, the obtained model – although it’s good illustra-
tive properties – does not produce fits of experimental data of
sufficient quality. The reason for this is that the disintegration
behavior is not monotonous on the whole disintegration time-
line. For example, the lactose-based formulations were
disintegrating by losing larger pieces of mass, hence producing
“step-wise” profiles. Such profiles produce poor fitting of the
exponential equations, hence we had to discard this approach.
In order to take into account such inhomogeneous effects the
differential model should be modified or substituted by
another, – perhaps, discrete – model.
An alternative polynomial fit of the curves was not favor-
able due to a potential risk of over fitting.
For this publication we used a simplified linear model,
which gave best results in all encountered situations.
Utilizing this approach, we can determine the residence
time of the pharmaceutical compact on the tensiometer
sample basket.
Optimal Type I Disintegration of FCC
Figure 6 shows a correlation plot between the amount of
absorbed water after 90 s and residence time for the differ-
ent disintegration types. Due to very long or even unlimited
residence time, disintegration type II and type IV were of no
interest for the production of ODTs. Although the majority
of formulations of disintegration type III had a residence
time below 3 min, type III was limited by nonuniform
disintegration. Disintegration type I showed the shortest
residence time and was therefore the most appropriate for
producing ODTs. Within type I, the formulations are better
the shorter the residence time and the lower the amount of
absorbed water after 90 s. The absorbed amount of water is
important with respect to patient compliance in the clinical
setting. We assume that a pleasant mouth feel can be
achieved with tablets dispersing in small amounts of saliva.
If more saliva is absorbed by the ODT, patient’s mouth feels
dry, and swallowing of the tablet becomes difficult.
Therefore, we conclude that FCC-based formulations were
the best. When combined with disintegrants, FCC formula-
tions showed a disintegration pattern of type I, comparable
to that of the market reference drug, risperidone oro.
CONCLUSION
ODTs are designed to disperse within seconds. The prereq-
uisite for reliable classification and quantification of disinte-
gration properties of ODTs is the availability of a fast
analytical method.
In order to compare ODT tablet formulations containing
FCC, we introduced a new method to characterize the
disintegration/dispersion kinetics and swelling properties of
ODTs. With this method we were able to detect the exact
amount of absorbed water after 90 s, speed of water absorp-
tion, and residence time of a tablet placed on a basket
immersed into water with a single instrument.
We conclude that FCC has the required properties to
produce ODTs, such as a fast disintegration, and sufficient
mechanical strength. To fulfill the requirements for a short
disintegration time, the FCC formulations have to contain
superdisintegrants. The FCC formulations absorbed
smallest amount of water, which would enhance patient
compliance in the clinical setting.
FCC is a new pharmaceutical excipient, which can be
used to assist in the preparation of orally dispersible tablets.
ODTs prepared using FCC as main excipient are charac-
terized by a short disintegration time and high mechanical
strength. Thus, drug delivery to the buccal cavity or upper
esophageal regions can be achieved. The oral sensation after
ingesting FCC particles is expected to be favorable since
particles with a particle size below 15 μm are not felt in the
mouth (34). Further experiments are required to study the
friability and flowability of FCC particles being a prerequi-
site for large scale production.
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